Clinical trials: Immunoglobulin
Neoplasms
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 as a single agent and in combination with cetuximab and rituximab in participants with advanced solid and…
- Trial name
- NCT03783403
- Testing
- CC-95251, Rituximab, Cetuximab
- Where
- 31 sites in United States, Australia and 5 more
- Volunteers
- 206 people
- Sponsor
- Celgene
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease
- Trial name
- NCT02694770
- Testing
- Neihulizumab Treatment, Conventional Treatment
- Where
- 2 sites in United States
- Sponsor
- AbGenomics B.V Taiwan Branch
Relapsed/Refractory Aggressive B-Cell Lymphoma
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810).
- Trial name
- CLIO-1 (NCT02651662)
- Testing
- cemiplimab, odronextamab
- Where
- 30 sites in United States, Austria and 4 more
- Volunteers
- 105 people
- Sponsor
- Regeneron Pharmaceuticals
Non Small Cell Lung Cancer, Cervical Cancer
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
The main goal of this study is to evaluate how safe and tolerable RNDO-564 is and to identify the best dose of RNDO-564 as a single agent and in combination with pembrolizumab.
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
- Trial name
- NCT07218003
- Testing
- RNDO-564, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 149 people
- Sponsor
- Rondo Therapeutics
Multiple Sclerosis
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims…
- Trial name
- NCT07566988
- Where
- United States
- Volunteers
- 2,604 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis
- Trial name
- NCT00646386
- Testing
- adalimumab
- Volunteers
- 315 people
- Sponsor
- Abbott
Rheumatoid Arthritis
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With Methotrexate
The purpose of the study is to assess the safety and efficacy of adalimumab compared to placebo in subjects with rheumatoid arthritis on methotrexate therapy.
- Trial name
- NCT00235859
- Testing
- adalimumab, methotrexate
- Volunteers
- 128 people
- Sponsor
- Abbott
Carcinoma, Non-Small-Cell Lung
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1-2 study of MM-121 in combination with standard therapy for non-small cell lung cancer (NSCLC).
- Trial name
- NCT00994123
- Testing
- MM-121, Erlotinib
- Where
- 38 sites in United States, Canada and 4 more
- Volunteers
- 162 people
- Sponsor
- Merrimack Pharmaceuticals
COVID19, COVID-19
At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study
Radish Health and ProofPilot in coordination with Sanesco are running this study to help establish whether the Premier Biotech COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma Authorized for distribution under…
- Conditions
- COVID19, COVID-19, Coronavirus
- Trial name
- NCT04393961
- Testing
- Premier Biotech COVID-19 IgG/IgM Rapid test Cassette
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ProofPilot
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) in patients with active RA who are unresponsive or intolerant to treatment with…
- Trial name
- NCT01606761
- Testing
- Sirukumab
- Where
- 201 sites in United States, Argentina and 20 more
- Volunteers
- 878 people
- Sponsor
- Janssen Research & Development, LLC
Fallopian Tube Cancer, Ovarian Cancer
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00004064
- Testing
- oregovomab
- Where
- 16 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- AltaRex
Diffuse Large B-Cell Lymphoma, B-Cell Malignancies
A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell Malignancies
The purpose of this study is to test the safety and tolerability of BG-T0050 and to identify the recommended dose and dosing schedule (including dose levels and timing) that can be taken without having serious side effects in…
- Trial name
- NCT07881211
- Testing
- BG-T0050
- Volunteers
- 70 people
- Sponsor
- BeOne Medicines
Advanced Ovarian Cancer, Triple Negative Breast Cancer
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
This is Phase IB, open label, non-randomized study designed to investigate the dose, safety, pharmacokinetics and anti-tumor activity of RO6870810 in combination with a fixed dose of atezolizumab.
- Trial name
- NCT03292172
- Testing
- Atezolizumab, RO6870810
- Where
- 11 sites in United States, Australia and 3 more
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin
A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)
Subjects were randomized to receive either tositumomab (Anti-B1 Antibody) and iodine I 131 tositumomab (Arm A) or unlabeled tositumomab (Arm B).
- Trial name
- NCT01573000
- Testing
- Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Osteoporosis, Postmenopausal
Efficacy and Safety of MW031 in PMO Subjects
This study is a multicenter, randomized, double-blinded, placebo-controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW031 in Chinese postmenopausal osteoporotic subjects with increased bone…
- Trial name
- NCT05215977
- Testing
- MW031
- Where
- China
- Volunteers
- 448 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Advanced Solid Tumors
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
Detailed Description: This is a multicenter, open-label, multiple-dose, first in human(FIH) Phase 1/2a trial. The Phase 1 portion uses the Bayesian optimal interval (BOIN) design to escalate doses and determine the maximum…
- Trial name
- NCT07772934
- Testing
- VBC117
- Where
- 12 sites in Australia, China
- Volunteers
- 260 people
- Sponsor
- VelaVigo Bio Inc
Hematological Malignancies
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.
- Trial name
- MajesTEC-1 (NCT03145181)
- Testing
- Teclistamab (IV), Teclistamab(SC)
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid…
- Trial name
- NCT00279734
- Testing
- Tetanus + pnemococcal vaccines alone, Abatacept + vaccines
- Where
- 3 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4 as a treatment for early stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071071
- Testing
- HuMax-CD4
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genmab
Bronchial Asthma
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks
- Trial name
- NCT07054034
- Testing
- MG-ZG122 Humanized Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.